BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Novo Nordisk and Eli Lilly Remain Underrated Despite GLP-1 Drug Potential
Novo Nordisk and Eli Lilly Remain Underrated Despite GLP-1 Drug Potential
15
2
BTCCSquare news:
Novo Nordisk and Eli Lilly, two healthcare giants, continue to defy expectations with their GLP-1 weight loss drugs. Novo Nordisk's stock has surged 400% over five years, while Eli Lilly's shares climbed 67%. Despite recent volatility, both companies appear undervalued as the market underestimates their growth potential.
The GLP-1 drug market is poised for expansion, with treatments like Wegovy and Zepbound already approved. These drugs curb appetite, offering significant weight loss benefits. Yet, high costs—exceeding $1,000 per month—remain a barrier for widespread adoption. Regulatory changes, including potential Medicare coverage under the TRUMP administration, could dramatically shift the landscape.
By:
